切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2020, Vol. 16 ›› Issue (05) : 615 -620. doi: 10.3877/cma.j.issn.1673-5250.2020.05.017

所属专题： 文献；

综述

非编码RNA在宫颈癌患者预后评估中的价值
孔党伊1, 王伟1, 郝敏1,†()   
  1. 1. 山西医科大学附属第二医院妇产科，太原　030000
  • 收稿日期:2020-01-08 修回日期:2020-09-10 出版日期:2020-10-01
  • 通信作者: 郝敏

Evaluation value of non-coding RNA in prognosis of patients with cervical cancer

Dangyi Kong1, Wei Wang1, Min Hao1,†()   

  1. 1. Department of Obstetrics and Gynecology, Second Affiliated Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China
  • Received:2020-01-08 Revised:2020-09-10 Published:2020-10-01
  • Corresponding author: Min Hao
  • Supported by:
    National Natural Science Foundation of China(81972452); Key Research and Development Projects of Shanxi Province(201803D31121, 201903D321152)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孔党伊, 王伟, 郝敏. 非编码RNA在宫颈癌患者预后评估中的价值[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(05): 615-620.

Dangyi Kong, Wei Wang, Min Hao. Evaluation value of non-coding RNA in prognosis of patients with cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(05): 615-620.

宫颈癌是妇科最常见的恶性肿瘤之一，其发病率和死亡率均位居全球女性癌症第4位。随着宫颈癌筛查技术的开展及人乳头瘤病毒(HPV)疫苗的投入使用，发达国家宫颈癌发病率呈明显下降趋势。而在发展中国家，由于经济落后及其他原因，宫颈癌发病率下降趋势并不显著。对于宫颈癌术后患者，目前临床上多采用定期监测血清鳞状细胞癌抗原(SCC)、糖类抗原(CA)125等指标评估宫颈癌复发可能性。但是，这些指标单独使用时均存在缺陷，故寻找可更好评估宫颈癌患者预后的生物标志物迫在眉睫。目前已有研究结果显示，非编码RNA(ncRNA)在评估宫颈癌预后中起着重要作用，而微小RNA(miRNA)、长链ncRNA(lncRNA)及环状RNA(circRNA)这3种ncRNA是目前研究热点。笔者拟对miRNA、lncRNA及circRNA这3种ncRNA在宫颈癌患者预后中的评估价值进行阐述。

关键词: 宫颈肿瘤, 微RNAs, RNA, 未翻译, 长链非编码RNA, 环状RNA, 预后, 女(雌)性

Cervical cancer is one of the most common malignant tumors in gynecology, and its morbidity and mortality rank fourth among women′s cancers worldwide. With the development of cervical cancer screening technology and the use of human papillomavirus (HPV) vaccines, the incidence of cervical cancer has decreased significantly in developed countries.While in developing countries, the incidence of cervical cancer has not decreased significantly due to economic backwardness and other reasons. For patients with cervical cancer after surgery, regular monitoring of squamous cell carcinoma antigen (SCC), carbohydrate antigen (CA)125 and other indicators are used in clinical practice to assess the possibility of recurrence of cervical cancer. However, these indicators are flawed when used alone, so it is urgent to find the biomarkers for better assessment of prognosis of patients with cervical cancer. At present, results of studies have shown that non-coding RNA(ncRNA) plays an important role in evaluating prognosis of patients with cervical cancer, and micro RNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA) are the current research hotspots. In this paper, the evaluation values of miRNA, lncRNA and circRNA in assessment of the prognosis of patients with cervical cancer are reviewed as follows.

Key words: Uterine cervical neoplasms, MicroRNAs, RNA, untranslated, Long non-coding RNA, Circular RNA, Prognosis, Female
[1]
Peng L, Yuan X, Jiang B, et al. LncRNAs: key players and novel insights into cervical cancer[J]. Tumour Biol, 2016, 37(3): 2779-2788. DOI: 10.1007/s13277-015-4663-9.
[2]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3]
王宁，刘硕，杨雷，等. 2018全球癌症统计报告解读[J/CD]. 肿瘤综合治疗电子杂志，2019, 5(1): 87-97. DOI: 10.12151/JMCM.2019.01-10.
[4]
Cheng Y, Yang S, Shen Y, et al. The role of high-risk human papillomavirus-related long non-coding RNAs in the prognosis of cervical squamous cell carcinoma[J]. DNA Cell Biol, 2020, 39(4): 645-653. DOI: 10.1089/dna.2019.5167.
[5]
Dou X, Zhou Q, Wen M, et al. Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor[J]. Front Pharmacol, 2019, 10: 1700. DOI: 10.3389/fphar.2019.01700.
[6]
Salvatici M, Achilarre MT, Sandri MT, et al. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: role in the early diagnosis of recurrence[J]. Gynecol Oncol, 2016, 142(1): 115-119. DOI: 10.1016/j.ygyno.2016.04.029.
[7]
Zhang Y, Na R, Wang X. LncRNA WT1-AS up-regulates p53 to inhibit the proliferation of cervical squamous carcinoma cells[J]. BMC Cancer, 2019, 19(1): 1052. DOI: 10.1186/s12885-019-6264-2.
[8]
Sasamoto N, Babic A, Rosner BA, et al. Development and validation of circulating CA125 prediction models in postmenopausal women[J]. J Ovarian Res, 2019, 12(1): 116. DOI: 10.1186/s13048-019-0591-4.
[9]
Foster W. Diagnosing endometriosis: CA125 rules in, but not out[J]. BJOG, 2016, 123(11): 1769. DOI: 10.1111/1471-0528.14224.
[10]
Tang X, Liu S, Ding Y, et al. Serum circular FoxO3a serves as a novel prognostic biomarker in squamous cervical cancer[J]. Cancer Manag Res, 2020, 12: 2531-2540. DOI: 10.2147/CMAR.S243329.
[11]
Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm[J]. Cancer Res, 2017, 77(15): 3965-3981. DOI: 10.1158/0008-5472.CAN-16-2634.
[12]
Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview[J]. Methods Mol Biol, 2017, 1509: 1-10. DOI: 10.1007/978-1-4939-6524-3_1.
[13]
Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans[J]. Nature, 2000, 403(6772): 901-906. DOI: 10.1038/35002607.
[14]
Wang J, Liu S, Shi J, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma[J]. Cancer Biother Radiopharm, 2019, 34(10): 605-613. DOI: 10.1089/cbr.2019.2939.
[15]
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med, 2012, 4(3): 143-159. DOI: 10.1002/emmm.201100209.
[16]
Huang C, Yu M, Yao X. MicroRNA-17 and the prognosis of human carcinomas: a systematic review and Meta-analysis[J]. BMJ Open, 2018, 8(5): e018070. DOI: 10.1136/bmjopen-2017-018070.
[17]
Park S, Kim J, Eom K, et al. MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer[J]. BMC Cancer, 2019, 19(1): 419. DOI: 10.1186/s12885-019-5620-6.
[18]
Wang Q, Qin J, Chen A, et al. Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer[J]. Tumour Biol, 2015, 36(5): 3703-3708. DOI: 10.1007/s13277-014-3009-3.
[19]
Chen S, Gao C, Wu Y, et al. Identification of prognostic miRNA signature and lymph node metastasis-related key genes in cervical cancer[J]. Front Pharmacol, 2020, 11: 544. DOI: 10.3389/fphar.2020.00544.
[20]
Wei W, Liu C. Prognostic and predictive roles of microRNA 411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer[J]. Mol Med Rep, 2020, 21(1): 267-281. DOI: 10.3892/mmr.2019.10826.
[21]
Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 1015. DOI: 10.3390/cells8091015.
[22]
Hu X, Sood AK, Dang CV, et al. The role of long noncoding RNAs in cancer: the dark matter matters[J]. Curr Opin Genet Dev, 2018, 48: 8-15. DOI: 10.1016/j.gde.2017.10.004.
[23]
Yang M, Wang M, Li X, et al. The role of lncRNAs in signaling pathway implicated in CC[J]. J Cell Biochem, 2019, 120(3): 2703-2712. DOI: 10.1002/jcb.26835.
[24]
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer[J]. Genomics Proteomics Bioinform, 2016, 14(1): 42-54. DOI: 10.1016/j.gpb.2015.09.006.
[25]
Chandra GS, Nandan TY. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets[J]. Int J Cancer, 2017, 140(9): 1955-1967. DOI: 10.1002/ijc.30546.
[26]
王文豪，王卉，郝敏. 宫颈癌与叶酸相关信号通路的研究进展[J/CD]. 中华妇幼临床医学杂志(电子版)，2020，16(2): 245-248. DOI: 10.3877/cma.j.issn.1673-5250.2020.02.018.
[27]
Zhang L, Yao HR, Liu SK, et al. Long noncoding RNA ROR1？AS1 overexpression predicts poor prognosis and promotes metastasis by activating Wnt/β-catenin/EMT signaling cascade in cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(6): 2928-2937. DOI: 10.26355/eurrev_202003_20656.
[28]
Zeng J, Ma YX, Liu ZH, et al. LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21): 9277-9285. DOI: 10.26355/eurrev_201911_19420.
[29]
Wang X, Zhang J, Wang Y. Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability[J]. Am J Transl Res, 2019, 11(8): 4909-4921.
[30]
Yang HY, Huang CP, Cao MM, et al. Long non-coding RNA CRNDE may be associated with poor prognosis by promoting proliferation and inhibiting apoptosis of cervical cancer cells through targeting PI3K/AKT[J]. Neoplasma, 2018, 65(6): 872-880. DOI: 10.4149/neo-2018-171225N841.
[31]
Zheng JJ, Du XJ, Wang HP, et al. Long non-coding RNA 00152 promotes cell proliferation in cervical cancer via regulating miR-216b-5p/HOXA1 axis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(9): 3654-3663. DOI: 10.26355/eurrev_201905_17789.
[32]
Wang Y, Lu T, Wang Q, et al. Circular RNAs: crucial regulators in the human body (Review)[J]. Oncol Rep, 2018, 40(6): 3119-3135. DOI: 10.3892/or.2018.6733.
[33]
Wu Q, Li P, Wu M, et al. Deregulation of circular RNAs in cancer from the perspectives of aberrant biogenesis, transport and removal[J]. Front Genet, 2019, 10: 16. DOI: 10.3389/fgene.2019.00016.
[34]
Huang J, Zhou Q, Li Y. Circular RNAs in gynecological disease: promising biomarkers and diagnostic targets[J]. Biosci Rep, 2019, 39(5): BSR20181641. DOI: 10.1042/BSR20181641.
[35]
Kristensen LS, Andersen MS, Stagsted L, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691. DOI: 10.1038/s41576-019-0158-7.
[36]
Song T, Xu A, Zhang Z, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075[J]. J Cell Physiol, 2019, 234(8): 14296-14305. DOI: 10.1002/jcp.28128.
[37]
Yu X, Xiao W, Song H, et al. CircRNA_100876 sponges miR-136 to promote proliferation and metastasis of gastric cancer by upregulating MIEN1 expression[J]. Gene, 2020, 748: 144678. DOI: 10.1016/j.gene.2020.144678.
[38]
Mao Y, Zhang L, Li Y. circEIF4G2 modulates the malignant features of cervical cancer via the miR 218/HOXA1 pathway[J]. Mol Med Rep, 2019, 19(5): 3714-3722. DOI: 10.3892/mmr.2019.10032.
[39]
Ou R, Lv J, Zhang Q, et al. circAMOTL1 motivates AMOTL1 expression to facilitate cervical cancer growth[J]. Mol Ther Nucleic Acids, 2020, 19: 50-60. DOI: 10.1016/j.omtn.2019.09.022.
[1] 闫文, 谢兴文, 顾玉彪, 雷宁波, 马成, 于文霞, 高亚雄, 张磊. 微小RNA与全膝关节置换术后深静脉血栓的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 842-846.
[2] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[3] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[4] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[5] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[6] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[7] 鲁鑫, 许佳怡, 刘洋, 杨琴, 鞠雯雯, 徐缨龙. 早期LC术与PTCD续贯LC术治疗急性胆囊炎对患者肝功能及预后的影响比较[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 648-650.
[8] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[9] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[10] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[11] 陆萍, 邹健. 凝血和纤维蛋白溶解标志物的动态变化对急性胰腺炎患者预后的评估价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 427-432.
[12] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[13] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号